France: Tissium closes €38.75m Series B

Wound treatment developer Tissium has raised €38.75m (US$42.8m) Series B funding to support the company’s expansion globally, particularly in the fields of nerve repair, cardiovascular and gastroenterology treatments. Funds will also be used to creating a streamlined clinical development and regulatory process across multiple geographies and to streamline the company’s manufacturing facility in Lille. “This…

You must be a HMI Subscriber to view this content. Please log in or subscribe below.

Subscribe Now »